$BMY Headlines Merck hits a new high as analyst sees

New Post Public Reply Private Reply Replies (0) Message Board

Jan 31, 2014 at 2:44 PM

$BMY Headlines

Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 5:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 3:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 8:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 5:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 2:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 8:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 2:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 12:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 12:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 12:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 3:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - Russ Britt
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Nasdaq Composite rattles cage on the 4,000 mark 11:29 a.m. Nov. 25, 2013 - Michael Ashbaugh
S&P, Dow hold tightly to record territory 10:36 a.m. Nov. 4, 2013 - Michael Ashbaugh
J.C. Penney, Bristol-Myers top S&P 500 6:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 3:58 p.m. Oct. 28, 2013 - Victor Reklaitis

6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014 7:52 a.m. Today - Seeking Alpha
5 Stocks Pulling The Drugs Industry Downward 12:02 p.m. Jan. 29, 2014 - TheStreet.com
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
'Mad Money' Lightning Round: Sell, Sell, Sell Windstream 6:00 a.m. Jan. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Agilent Is Sensational (1/28/14) 5:16 a.m. Jan. 29, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Where Have All the Sellers Gone? 8:34 p.m. Jan. 28, 2014 - TheStreet.com
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Questcor 57% January Upside Eclipsed Healthcare Dogs 9:36 a.m. Jan. 28, 2014 - Seeking Alpha
The Acquisition Of Mills Pharmaceuticals Put Another Arrow In The Quiver Of Galena 6:07 p.m. Jan. 27, 2014 - Seeking Alpha
Bristol-Myers - Nivolumab's Delays Warrant Friday's Sell-Off 3:21 p.m. Jan. 27, 2014 - Seeking Alpha
One Factor Driving Bristol-Myers Squibb (BMY) Down Today 3:06 p.m. Jan. 27, 2014 - TheStreet.com
Merck +2.8% as Morgan Stanley sees opening for new cancer drug 12:32 p.m. Jan. 27, 2014 - Seeking Alpha
What A Surprise 12:46 a.m. Jan. 26, 2014 - Seeking Alpha
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Jan. 25, 2014 - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Bristol-Myers Squibb's CEO Discusses Q4 2013 Results - Earnings Call Transcript 2:49 p.m. Jan. 24, 2014 - Seeking Alpha
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment 2:21 p.m. Jan. 24, 2014 - benzinga.com
Bristol Q4 Beats, But Nivolumab Still Worries Market 12:51 p.m. Jan. 24, 2014 - Investors Business Daily
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy 10:20 a.m. Jan. 24, 2014 - InvestorPlace.com

Critical Alerts For Facebook, News Corp, Bristol Myers, Akamai, and Total SA Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
The American Cancer Society and Stand Up To Cancer Announce Collaborative Research Effort 9:00 a.m. Jan. 29, 2014 - PR Newswire - PRF
Sundia Appoints a New Board Advisor 8:00 a.m. Jan. 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results 7:30 a.m. Jan. 24, 2014 - BusinessWire - BZX
Theravance Appoints Frank Pasqualone Senior Vice President, Operations 4:05 p.m. Jan. 23, 2014 - Marketwire
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
Relyco Closes Out Successful 2013 and Kicks Off 25th Anniversary in 2014 10:05 a.m. Jan. 22, 2014 - Marketwire
Pharm-Bio Building Boom: More Than $20 Billion Set for 2014 North American Capital Project Starts, an Industrial Info News Alert 6:15 a.m. Jan. 17, 2014 - Marketwire
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative 8:30 a.m. Jan. 16, 2014 - BusinessWire - BZX
Regulatory Updates, Management Changes, and Conference Calls - Research Report on Bristol-Myers Squibb, Amgen, St. Jude Medical, Boston Scientific, and Mylan 8:00 a.m. Jan. 15, 2014 - PR Newswire - PRF
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes 2:02 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors 9:00 a.m. Jan. 9, 2014 - PR Newswire
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C 8:29 a.m. Jan. 9, 2014 - BusinessWire
Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena 8:00 a.m. Jan. 9, 2014 - PR Newswire
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin) 5:05 p.m. Jan. 8, 2014 - BusinessWire
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency 6:59 a.m. Jan. 8, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24 3:15 p.m. Jan. 6, 2014 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Atlas-SSI Expands Grip in Water Control Space

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...

Q32 Bio Eyes New Horizons with Bempikibart's Potentials

Q32 Bio Steers Forward: New Insights from Chief Results Today's update isn't just another quarterly snooze-fest—it’s a nudge in a crucial direction for Q32 Bio (NASDAQ:QTTB). After a bold brush with the European Academy of Dermatology and Venereology (EADV) Congress 2026, the company laid out a plan and a half, showing its hand with bempikibart for alopecia areata...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

DarioHealth Taps Palumbo to Drive Healthcare Evolution

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Hyundai Pushes Hydrogen Boundaries at 2026 Expo

A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...

Greasezilla to Process 15M Gallons of FOG Yearly

Greasezilla Steps Up for FOG Processing If there’s one thing that makes dealing with wastewater a greasy business, it’s FOG - fats, oils, and grease. It’s the stuff nightmares are made of for any utility trying to keep their pipes clear and their operations running smooth. Now, Greasezilla is stepping into the spotlight at one of the country's largest wastewater...

Natixis' $100M Student Challenge Mixes Real Stakes

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Camtek Hits Record Q3 Revenue; Strong Growth Ahead

Camtek's Record Performance in Q3 2026 Diving straight into the numbers, Camtek (NASDAQ:CAMT) just posted a staggering $161.3 million in Q3 2026 revenues, marking a 21% jump from the previous quarter. Now, that kind of growth isn't just impressive; it's a wake-up call to any investor still snoozing on semiconductor stocks. They're looking at revenues of around $180...

Sinch Partners with SpaceX's Super Intelligence Network

Piecing Together the New Sinch and SpaceX Partnership Here's a juicy piece of tech news that might just tickle those investing antennas: Sinch AB's teaming up with the SpaceX Super Intelligence Network as a Marketplace Partner. Let's rip the Band-Aid off about why this development has investors riled and buzzing with expectation. Now, Sinch might not be the first company...

Askey & Icom Team Up: Trading Airwaves for Partnerships

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...